Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and ...
In this episode of Managed Care Cast, Ella Hohmann speaks with Douglas Marks, MD, breast medical oncologist and associate ...
Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established ...
Ectopic germinal centers (GCs) were found to be a prognostic factor for poor outcomes for patients with thymoma-associated ...
JoAnn Manson, MD, shares findings from the VIVID trial on vitamin D, the timing of use, and its potential to reduce long ...
Across tumor types, 1-year NGS uptake rose substantially from 2018 to 2022, reaching 74.5% in aNSCLC and 78.1% in mCRC, but ...
A new systematic review and meta-analysis appearing in the Journal of Sport and Health Science suggests that combining strength and aerobic exercise may offer greater improvements ...
With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it. One of the most pressing financial debates in ...
Two-year data confirm DOR/ISL delivers durable viral suppression—even in patients with high viral loads or advanced disease.
Reclassifying vaccines as shared clinical decision-making creates an additional financial risk. If ACIP no longer ...
Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results